Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer`s Disease (88KB)
(WorldNews Japan)

May 24, 2018 For Immediate Release Company name Otsuka Holdings Co., Ltd. Representative Tatsuo Higuchi President and Representative Director, CEO Code number 4578 First Section , Tokyo Stock Exchange Inquiries Yuji Kogure Director, Investors Relations Department Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer`s Disease Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies` third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer`s type will commence in June. Approximately 300...